Hitting the target in IDH2 mutant AML

被引：3
|
作者：
Wouters, Bas J. [1 ]
机构：
[1] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
来源：
BLOOD | 2017年 / 130卷 / 06期
关键词：
DIFFERENTIATION; LEUKEMIA; CELLS;
D O I：
10.1182/blood-2017-06-790394
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Stein et al(1) demonstrate the feasibility and clinical efficacy of targeted inhibition of mutant isocitrate dehydrogenase 2 (IDH2) in patients with acute myeloid leukemia (AML). In a related paper, Amatangelo et al(2) investigate mechanisms of response in samples derived from the same patients.
引用
收藏
页码：693 / 694
页数：2
相关论文
共 50 条
  • [31] Plk1 regulates mutant IDH1 enzyme activity and mutant IDH2 ubiquitination in mitosis
    Reddy, M. Saikiran
    Bhattacharjee, Debanjan
    Jain, Nishant
    CELLULAR SIGNALLING, 2022, 92
  • [32] The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
    Samah Nassereddine
    Coen J. Lap
    Faysal Haroun
    Imad Tabbara
    Annals of Hematology, 2017, 96 : 1983 - 1991
  • [33] NPMC COOPERATES WITH MUTANT IDH2 TO INDUCE ACUTE MYELOID LEUKEMIA
    Ogawara, Yoko
    Katsumoto, Takuo
    Aikawa, Yukiko
    Kagiyama, Yuki
    Kitabayashi, Issay
    EXPERIMENTAL HEMATOLOGY, 2013, 41 (08) : S55 - S55
  • [34] ADJUVANT POST-SURGERY TREATMENT OF RECURRENT IDH2 MUTANT ANAPLASTIC OLIGODENTROGLIOMA (AO) WITH IDH2 INHIBITOR, ENASIDENIB: A CASE REPORT
    Kong, Xiao-Tang
    Fu, Beverly Dan
    Myung, Joon
    Bota, Daniela
    NEURO-ONCOLOGY, 2023, 25
  • [35] The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
    Abou Dalle, Iman
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (07) : 163 - 173
  • [36] Design, synthesis, AML activity and molecular modeling of novel IDH2 inhibitors
    Jin, Ruyi
    Tang, Tian
    Zhou, Sha
    Tang, Yuping
    Guo, Hui
    Wang, Yuwei
    Nie, Fayi
    BIOORGANIC CHEMISTRY, 2023, 130
  • [37] Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups
    F Damm
    F Thol
    I Hollink
    M Zimmermann
    K Reinhardt
    M M van den Heuvel-Eibrink
    C M Zwaan
    V de Haas
    U Creutzig
    J-H Klusmann
    J Krauter
    M Heuser
    A Ganser
    D Reinhardt
    C Thiede
    Leukemia, 2011, 25 : 1704 - 1710
  • [38] Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
    Thomas, Daniel
    Majeti, Ravindra
    CANCER DISCOVERY, 2017, 7 (05) : 459 - 461
  • [39] Oncometabolite-Independent Anti-Apoptotic Feature Via Phospholipid Metabolic Adaptation in IDH2 Mutant AML Cells
    Morishima, Tatsuya
    Takahashi, Koichi
    Chin, Desmond Wai Loon
    Tokunaga, Kenji
    Arima, Yuichiro
    Matsuoka, Masao
    Suda, Toshio
    Takizawa, Hitoshi
    BLOOD, 2022, 140 : 3012 - 3013
  • [40] Mutant IDH as therapeutic target in AML/MDS: where Epigenetics meets metabolomics
    Heuser, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 225 - 225
12345